Dennis Ding
Stock Analyst at Jefferies
(2.20)
# 2,831
Out of 5,149 analysts
15
Total ratings
40%
Success rate
12.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FOLD Amicus Therapeutics | Downgrades: Hold | $16 → $15 | $14.36 | +0.97% | 2 | Jan 22, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $28.10 | -28.83% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $29.32 | -11.32% | 2 | Sep 3, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $40.68 | +35.20% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.93 | +314.51% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $29.68 | +17.92% | 1 | Sep 20, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.67 | +49.89% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $3.63 | +65.29% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $1.19 | +2,000.84% | 1 | May 7, 2024 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $35.97 | -38.84% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $32.83 | -26.90% | 1 | Dec 19, 2022 |
Amicus Therapeutics
Jan 22, 2026
Downgrades: Hold
Price Target: $16 → $15
Current: $14.36
Upside: +0.97%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $28.10
Upside: -28.83%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $29.32
Upside: -11.32%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $40.68
Upside: +35.20%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.93
Upside: +314.51%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $29.68
Upside: +17.92%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.67
Upside: +49.89%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $3.63
Upside: +65.29%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $1.19
Upside: +2,000.84%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $35.97
Upside: -38.84%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $32.83
Upside: -26.90%